# Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct07387003` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07387003](<https://clinicaltrials.gov/study/NCT07387003>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07387003

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 345 participants.

## Technical summary

Registry record NCT07387003. Randomized; no masking; primary purpose treatment. Start 2026-04-10 (anticipated); primary completion 2027-02-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 345 participants (planned count; ClinicalTrials.gov record NCT07387003, source copy `cardio:ctgov-nct07387003-2026-04-15`, retrieved 2026-10-26)
- Planned start: 2026-04-10 (anticipated) (ClinicalTrials.gov record NCT07387003, source copy `cardio:ctgov-nct07387003-2026-04-15`, retrieved 2026-10-26)
- Primary completion: 2027-02-11 (anticipated) (ClinicalTrials.gov record NCT07387003, source copy `cardio:ctgov-nct07387003-2026-04-15`, retrieved 2026-10-26)
- Completion: 2027-09-23 (anticipated) (ClinicalTrials.gov record NCT07387003, source copy `cardio:ctgov-nct07387003-2026-04-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07387003, source copy `cardio:ctgov-nct07387003-2026-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07387003-2026-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes (T2DM)
- Intervention (Drug): GZR101-80
- Intervention (Drug): GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)
- Lead sponsor: Gan & Lee Pharmaceuticals.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Gan & Lee Pharmaceuticals. (`cardio:org-gan-lee-pharmaceuticals`)

## Provenance

Content hash: d8ad54c1fc06f013de4c7c82e22feaaa3d54361fea09fc58f9e1643fb289e5d4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
